Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Q3 2019 Earnings Conference Call November 6, 2019 8:30 AM ET
Company Participants
Allen Baharaff - Chairman, CEO & President
Yohai Stenzler - CFO & Controller
Liat Hayardeny - Chief Scientific Officer
Tali Gorfine - Chief Medical Officer
Conference Call Participants
Steven Seedhouse - Raymond James & Associates
Antonio Arce - H.C. Wainwright & Co.
Adam Walsh - Stifel, Nicolaus & Company
Paul O'Brien - Roth Capital
Mayank Mamtani - B. Riley FBR, Inc.
Kristen Kluska - Cantor Fitzgerald & Co.
Adheip Mally - Maxim Group
Operator
Good day, and welcome to Galmed Conference Call to discuss financial results for third quarter of 2019. Today's conference is being recorded.
Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs, as well as other statements that relate to future events. These statements are based on the beliefs and expectations of management as of today, and actual results, trends, timelines and projections relating to our financial position and projected development programs and pipeline could differ materially.
We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under heading Risk Factors described in our Annual Report on Form 20-F filed with SEC and the risks and uncertainties included in the Form 6-K filed with the SEC earlier today. Galmed assumes no obligation to update any forward-looking statements or information, which speaks as of the respective dates only.
I would now like to turn the call over to Allen Baharaff, President and Chief Executive Officer. Allen, please go ahead.
Allen Baharaff
Thank you, Steve. Good morning, and thank you for joining us
- Read more current GLMD analysis and news
- View all earnings call transcripts